2. Academic Validation
  3. Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold

Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold

  • Eur J Med Chem. 2022 Aug 5;238:114433. doi: 10.1016/j.ejmech.2022.114433.
Zhengnian Li 1,  Ryosuke Ishida 1,  Yan Liu 2,  Jinhua Wang 3,  Yina Li 3,  Yang Gao 3,  Jie Jiang 3,  Jianwei Che 3,  Jason M Sheltzer 4,  Matthew B Robers 5,  Tinghu Zhang 1,  Kenneth D Westover 2,  Behnam Nabet 6,  Nathanael S Gray 7
Affiliations

Affiliations

  • 1 Chemical and Systems Biology, Chem-H, Stanford Cancer Institute, Stanford Medicine, Stanford University, Stanford, CA, USA.
  • 2 Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
  • 3 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • 4 Yale University School of Medicine, New Haven, CT, USA.
  • 5 Promega Corporation, Madison, WI, USA.
  • 6 Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: bnabet@fredhutch.org.
  • 7 Chemical and Systems Biology, Chem-H, Stanford Cancer Institute, Stanford Medicine, Stanford University, Stanford, CA, USA. Electronic address: nsgray01@stanford.edu.
PMID: 35597007 DOI: 10.1016/j.ejmech.2022.114433
Abstract

Cyclin-dependent kinases (CDK) are attractive targets for drug discovery due to their wide range of cellular functions. CDK11 is an understudied CDK with roles in transcription and splicing, cell cycle regulation, neuronal function, and Apoptosis. In this study, we describe a medicinal chemistry campaign to identify a CDK11 Inhibitor. Employing a promising but nonselective CDK11-targeting scaffold (JWD-047), extensive structure-guided medicinal chemistry modifications led to the identification of ZNL-05-044. A combination of biochemical evaluations and NanoBRET cellular assays for target engagement guided the SAR towards a 2,4-diaminothiazoles CDK11 probe with significantly improved kinome-wide selectivity over JWD-047. CDK11 inhibition with ZNL-05-044 leads to G2/M cell cycle arrest, consistent with prior work evaluating OTS964, and impacts CDK11-dependent mRNA splicing in cells. Together, ZNL-05-044 serves as a tool compound for further optimization and interrogation of the consequences of CDK11 inhibition.

Keywords

CDK11; Kinase inhibitor; Serine/threonine protein kinase; Structure-activity relationship.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-155874
    99.91%, CDK11 Inhibitor
    CDK